Cargando…

The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma

Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, util...

Descripción completa

Detalles Bibliográficos
Autores principales: Patarat, Rathasapa, Riku, Shoji, Kunadirek, Pattapon, Chuaypen, Natthaya, Tangkijvanich, Pisit, Mutirangura, Apiwat, Puttipanyalears, Charoenchai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295309/
https://www.ncbi.nlm.nih.gov/pubmed/34290294
http://dx.doi.org/10.1038/s41598-021-94330-1
_version_ 1783725406367514624
author Patarat, Rathasapa
Riku, Shoji
Kunadirek, Pattapon
Chuaypen, Natthaya
Tangkijvanich, Pisit
Mutirangura, Apiwat
Puttipanyalears, Charoenchai
author_facet Patarat, Rathasapa
Riku, Shoji
Kunadirek, Pattapon
Chuaypen, Natthaya
Tangkijvanich, Pisit
Mutirangura, Apiwat
Puttipanyalears, Charoenchai
author_sort Patarat, Rathasapa
collection PubMed
description Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.001). Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47 ± 4.43, 28.01 ± 3.75, 29.64 ± 3.90) were lower than healthy group (34.23 ± 3.54, 32.90 ± 4.15, 32.18 ± 5.02) (p-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.9%, sensitivity of 77.6% and specificity of 75%. Also, we founded that our gene combination performs better than the current gold standard for HCC screening. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods.
format Online
Article
Text
id pubmed-8295309
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82953092021-07-22 The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma Patarat, Rathasapa Riku, Shoji Kunadirek, Pattapon Chuaypen, Natthaya Tangkijvanich, Pisit Mutirangura, Apiwat Puttipanyalears, Charoenchai Sci Rep Article Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.001). Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47 ± 4.43, 28.01 ± 3.75, 29.64 ± 3.90) were lower than healthy group (34.23 ± 3.54, 32.90 ± 4.15, 32.18 ± 5.02) (p-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.9%, sensitivity of 77.6% and specificity of 75%. Also, we founded that our gene combination performs better than the current gold standard for HCC screening. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods. Nature Publishing Group UK 2021-07-21 /pmc/articles/PMC8295309/ /pubmed/34290294 http://dx.doi.org/10.1038/s41598-021-94330-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Patarat, Rathasapa
Riku, Shoji
Kunadirek, Pattapon
Chuaypen, Natthaya
Tangkijvanich, Pisit
Mutirangura, Apiwat
Puttipanyalears, Charoenchai
The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_full The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_fullStr The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_full_unstemmed The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_short The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_sort expression of flna and clu in pbmcs as a novel screening marker for hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295309/
https://www.ncbi.nlm.nih.gov/pubmed/34290294
http://dx.doi.org/10.1038/s41598-021-94330-1
work_keys_str_mv AT pataratrathasapa theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT rikushoji theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT kunadirekpattapon theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT chuaypennatthaya theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT tangkijvanichpisit theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT mutiranguraapiwat theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT puttipanyalearscharoenchai theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT pataratrathasapa expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT rikushoji expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT kunadirekpattapon expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT chuaypennatthaya expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT tangkijvanichpisit expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT mutiranguraapiwat expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
AT puttipanyalearscharoenchai expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma